check_circleStudy Completed

Toothache

Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

Trial purpose

To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.

Key Participants Requirements

Sex

Both

Age

16 - 45 Years
  • - Healthy, ambulatory, male and female volunteers between 16 to 45
    - Scheduled to undergo surgical removal of 1 - 2 impacted third molars, one of which must be at least a partial mandibular bony impaction
    - No use of any analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, any other pain reliever (Over The Counter or prescription), or herbal supplements within 5 days of surgery
    - Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale
  • - History of hypersensitivity to naproxen sodium, aspirin (ASA), other NSAIDs, opioid analgesics, and similar pharmacological agents or components of the investigational products, including the placebo
    - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies
    - Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study
    - Current or past history of bleeding disorder(s)
    - History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)

Trial summary

Enrollment Goal
312
Trial Dates
June 2008 - August 2008
Phase
Phase 3
Could I Receive a placebo
Yes
Products
Aleve (Naproxen Sodium ER, BAY117031)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Jean Brown ResearchSalt Lake City, 84124, United States
Completed
Pharmaceutical Product Development, LLCAustin, 78744, United States
Completed
SCIREX-Premier Clinical ResearchAustin, 78705, United States

Primary Outcome

  • Summed Pain Intensity Difference (SPID)
    date_rangeTime Frame:
    0 to 24 hours post dose
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Total Pain Relief (TOTPAR)
    date_rangeTime Frame:
    0-24 hours post dose
    enhanced_encryption
    Safety Issue:
    No
  • Summed Pain Intensity Difference at Specific Time Intervals
    date_rangeTime Frame:
    0-16 hours post dose
    enhanced_encryption
    Safety Issue:
    No
  • Time to First Use of Rescue Medication
    date_rangeTime Frame:
    postdose to first use of rescue medication
    enhanced_encryption
    Safety Issue:
    No
  • Global Assessment of the Investigational Product as a Pain Reliever
    date_rangeTime Frame:
    at 24 hours postdose or immediately before first use of rescue medication
    enhanced_encryption
    Safety Issue:
    No
  • Time to Onset of Effect
    date_rangeTime Frame:
    from postdose to onset of first perceptible and meaningful pain relief for up to 6 hours
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental Pain
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Double Blind
Assignment
Parallel Assignment
Trial Arms
2